Highest-materiality recent filing
bioAffinity SAB webinar on CyPath Lung for early lung cancer detection on June 16
Society for Advanced Bronchoscopy hosts free webinar June 16, 7pm ET on CyPath Lung's role in early lung cancer detection.
bioAffinity Technologies announces Mexican patent allowance for CyPath Lung cancer detection method
Mexican patent allowance for flow-cytometry methods to detect lung cancer using CyPath Lung.
bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025
Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M
CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M
Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
CyPath® Lung case study shows test helped defer biopsy for high-risk patient with 30mm nodule
70-year-old female, 50 pack-year smoking history, 30mm lung nodule with high cancer risk by imaging and models.
bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16
CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.
bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections
Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
bioAffinity posts investor presentation on website; no financial details in filing
Presentation materials made available on company website on March 26, 2026.
bioAffinity Technologies announces virtual physician roundtable on CyPath® Lung for April 8, 2026
Webinar titled 'CyPath® Lung in Practice: A Physician Roundtable Discussion' on April 8, 2026 at 7 p.m. ET.
bioAffinity case study shows CyPath Lung avoided invasive biopsy in high-risk nodule patient
71-year-old former smoker with multiple lung nodules received CyPath Lung 'Unlikely Malignancy' result.
bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M
Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic
2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
Two directors not standing for re-election at bioAffinity Technologies' 2026 annual meeting
Robert Anderson and Roby Joyce informed the board on March 5, 2026 of their decisions not to stand for re-election.
Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.
Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.
CyPath Lung test was negative for a 79-year-old woman with suspicious LDCT finding, supporting surveillance over invasive biopsy.
bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules
CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
bioAffinity posts new presentation materials; no details in filing
Company published new investor presentation on its website as of February 10, 2026.
bioAffinity appoints three lung cancer specialists to Medical and Scientific Advisory Board
David Ost (MD Anderson), Daniel Sterman (NYU Langone) and J. Scott Ferguson (Univ. of Wisconsin) joined the advisory board.
bioAffinity Technologies sets 2026 Annual Meeting for April 30; proposal deadline Feb 14
Annual Meeting scheduled for April 30, 2026 at company's principal executive offices in San Antonio, TX.
bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS
Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.
Dr. Joyce (77) informed Company of desire to transfer 100% stock of Village Oaks Pathology to Dr. Humphreys; not due to disagreement.
bioAffinity adjourns special meeting due to lack of quorum; reconvenes Jan 19, 2026
Special meeting of stockholders adjourned Dec 19, 2025 because insufficient shares present for quorum.
CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.
bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M
Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg
October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
bioAffinity Technologies announces Australian patent acceptance for lung health platform
IP Australia accepted patent application AU 2019253111 for a flow cytometry-based platform to detect multiple lung diseases.
bioAffinity Technologies to present CyPath® Lung processing research at CHEST 2025
Poster presented Oct 22, 2025 by Rossella Titone, PhD at poster board #4324.
bioAffinity receives US patent allowance for AI-driven lung cancer diagnostic
USPTO allowed patent covering AI-built algorithm and flow cytometry platform for CyPath Lung test.
bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market
Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
bioAffinity Technologies closes $1.8M registered direct offering of 720K shares at $2.50/share
Issued 720,000 shares of common stock at $2.50/share; gross proceeds of ~$1.8M before fees.
bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD
CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.
bioAffinity closes $4.8M public offering; Nasdaq compliance extension received
Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.
bioAffinity Technologies announces 1-for-30 reverse stock split effective Sept 19, 2025
1-for-30 reverse stock split effective at open of trading on Nasdaq on September 19, 2025.
bioAffinity Technologies case study shows CyPath Lung detects cancer in ground-glass nodules
Case study: 66-year-old former smoker with 13mm ground-glass nodule; CyPath Lung returned 'likely malignant' result.
bioAffinity prepares presentation materials for H.C. Wainwright conference
Presentation materials furnished for use at H.C. Wainwright 27th Annual Global Investment Conference (Sep 8-10, 2025).
U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity
CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.
Increased floor price in May 2025 and August 2025 warrants from $0.10 to $0.15, effective August 12, 2025.
bioAffinity Technologies appoints Roberto Rios and John Oppenheimer to board; Gary Rubin resigns
Roberto Rios (CPA) and John J. Oppenheimer (M.D.) appointed to Board, each term expiring at 2026 annual meeting.
bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1
Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.
bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity
Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.
Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
CyPath® Lung detects Stage 1A lung cancer missed by standard tests in case study
CyPath Lung identified Stage 1A invasive mucinous adenocarcinoma in a 62-year-old female with heavy smoking history and COPD.
All seven proposals passed at July 25, 2025 Annual Meeting.
bioAffinity Technologies: CyPath® Lung detects Stage 1A tumor missed by PET scan, bronchoscopies
CyPath® Lung identified a Stage 1A neuroendocrine tumor after PET scan, bronchoscopies and serum tumor marker suggested non-cancerous inflammation.
bioAffinity Technologies receives Canadian patent allowance for CyPath Lung diagnostic
Canadian Patent Office allowed patent (No. 3,136,245) for method using flow cytometry and TCPP to detect lung cancer in sputum.
bioAffinity receives China patent allowance for lung cancer diagnostic using flow cytometry
CNIPA allowed patent 'System and Method for Determining Lung Health' covering use of antibodies and TCPP porphyrin to label sputum cells for lung cancer detection via flow cytometry.
bioAffinity receives Nasdaq delisting notice; equity of $1.44M below $2.5M minimum
Stockholders' equity was $1,439,404 as of March 31, 2025, well below the $2,500,000 minimum.
bioAffinity Technologies enters $5.8M ATM equity sales agreement with WallachBeth Capital
Entered ATM agreement with WallachBeth Capital to sell up to $5,801,000 of common stock.
On April 12, 2025, Stuart Diamond, a member of the board of directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), notified the Company of his decision not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.
Michael Dougherty notified bioAffinity Technologies, Inc. (the "Company") of his decision to resign from his position as the Company’s Chief Financial Officer and Principal Accounting Officer to pursue other opportunities.
the Board of Directors of the Company appointed, effective as of September 16, 2024, Michael Edwards, age 57, to serve as the Company’s Interim Chief Financial Officer and Principal Accounting Officer.
Max materiality 0.85 · Median 0.50 · Most common event other_material